BioSpace News Archive

[02-November-2017] SAN DIEGO, Nov. 2, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal second quarter ended September 30, 2017. Key Recent Developments EAP - In September 2017, the United States Food and Drug Administration (FDA) granted an

Five of the 6 patient responder sub-group (83%) had a primary diagnosis of diabetic nephropathy and 1 of the 6 responders (17%) had a primary diagnosis of IgA nephropathy.

Evonik Industries and Eli Lilly and Company (Lilly) today announced the renewal of a long-term agreement under which Evonik will supply active pharmaceutical ingredients (APIs) and intermediates for use in key Lilly human and veterinary drug products.

Cristal Therapeutics announced today that it has begun a Phase Ib clinical program of its lead nanomedicine candidate CriPec-docetaxel in patients with solid tumours.

MMJ is pleased to provide its quarterly activities report for the period ended 30 September 2017, together with its Appendix 4C.

Professor Bob Rastall, Professor of Food Biotechnology at the University of Reading, has presented research on an exciting, emerging area of microbiome modulation at the 5th Microbiome R&D and Business Collaboration Forum in San Diego.

Cambridge Epigenetix announced that it has appointed diagnostic experts, Hayden Jeffreys as Chief Operating Officer (COO) and Dr Joanne Mason as Vice President (VP) of Biomarker Discovery.

MorphoSys announced the upcoming presentation of data on the Company’s proprietary investigational hemato-oncological program MOR208 at the 59th American Society of Hematology (ASH) Annual Meeting, being held December 9-12, 2017 in Atlanta, Georgia/USA.

Medidata announced that it will host a Financial Analyst Day on Thursday, November 9, 2017 in New York City.

The Cellentia-H is the newest addition to Nipro’s growing line of high performance dialyzers.